Alexion pexelizumab fails second PRIMO study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alexion's terminal complement inhibitor pexelizumab fails to show statistical significance in the firm's second coronary artery bypass graft trial, PRIMO-CABG2. Alexion is assessing the implications of the results on its APEX-AMI study of the biologic in acute myocardial infarction. When pexelizumab failed the first PRIMO (Pexelizumab for Reduction in Infarction & Mortality) study in August 2003, Alexion said the results could be used to support an AMI indication (Pharmaceutical Approvals Monthly September 2003, p. 21). The APEX study has enrolled 3,000 patients, according to the firm...
You may also be interested in...
Alexion/P&G Pexelizumab Failed Phase III Could Compromise Partnership
A development partnership between Alexion and Procter & Gamble could be called into question following negative results of two Phase III trials of the terminal complement inhibitor pexelizumab
Alexion Pexelizumab Failed CABG Trial Could Support Acute MI Claim – Firm
Alexion’s failed pexelizumab Phase III coronary artery bypass graft surgery trial could serve as a supportive trial for an acute myocardial infarction indication, the firm says.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.